jama glp 1 A new JAMA Surgery study
Description
2026 review explains why telogen effluvium from rapid weight loss
Nausea, vomiting, diarrhea, constipation
Visual presentation of new weight loss medicine trial results can supplement standard published reports by condensing substantial amounts of complex technical information in an easily understood format that can potentially yield new study insights.
Retatrutide produces the greatest weight loss (up to 24.2%), followed by tirzepatide (up to 22.5%), then semaglutide (up to 14.9%), but retatrutide remains i...
Not a small trend anymore
Discover the best GLP-1 tracking apps
